Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Carisma Therapeutics ( (CARM) ) has provided an update.
On June 22, 2025, Carisma Therapeutics announced a merger agreement with OrthoCellix, a subsidiary of Ocugen, to create a Nasdaq-listed company focused on regenerative cell therapies for orthopedic diseases. The merger will result in OrthoCellix owning approximately 90% of the combined entity, with plans to initiate a Phase 3 clinical trial for its NeoCart® technology by the end of 2025, potentially impacting the market for cartilage repair solutions.
The most recent analyst rating on (CARM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Carisma Therapeutics stock, see the CARM Stock Forecast page.
Spark’s Take on CARM Stock
According to Spark, TipRanks’ AI Analyst, CARM is a Neutral.
Carisma Therapeutics’ overall score reflects its financial instability and valuation concerns as primary weaknesses. The technical analysis provides some positive indicators but is overshadowed by the financial and valuation challenges.
To see Spark’s full report on CARM stock, click here.
More about Carisma Therapeutics
Carisma Therapeutics is a biotechnology company focused on macrophage engineering to develop therapies for fibrosis and cancer. OrthoCellix, a subsidiary of Ocugen, specializes in regenerative cell therapies for orthopedic diseases, with its lead program NeoCart® aimed at repairing knee cartilage defects.
Average Trading Volume: 13,925,722
Technical Sentiment Signal: Sell
Current Market Cap: $18.43M
For detailed information about CARM stock, go to TipRanks’ Stock Analysis page.